Biosimilar

Brenzys

Biosimilar of:

ENBREL

Active Ingredient: etanercept

Drug Class: Biologics

Brenzys is not covered on the Reformulary. Reformulary Group has selected specific etanercept biosimilar to be covered: ERELZI, manufactured by Sandoz, a division of Novartis Canada. ERELZI is considered a preferred etanercept biosimilar as it offers the same clinical value at a lower net cost to the plan. ERELZI requires Special Authorization.

Brenzys is used to treat  
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis